DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, yesterday presented data at the annual meeting of the American Association for Cancer Research (AACR) in Denver, Colorado, showing that its BiTE(R) antibody MT110 can eliminate cancer stem cells (1). Cancer stem cells are thought to be responsible for resistance of human cancers to chemotherapy and for metastatic relapse. MT110 is in a phase 1 dose-escalating clinical trial in patients with lung or gastrointestinal cancer.
BiTE antibodies such as MT110 represent a novel class of therapeutic antibodies designed to direct the body's cell-destroying T cells against tumor cells. MT110 recognizes cancer cells expressing the epithelial cell adhesion molecule, or EpCAM, a target antigen that is highly and frequently expressed on the surface of many types of solid tumors. EpCAM also has been shown to be expressed on cancer stem cells (2) and to promote tumor formation (3). The data presented at AACR show that the BiTE antibody MT110 can direct T cells to eliminate EpCAM-expressing human colorectal cancer stem cells in cell culture. In addition, data from a study of MT110 in mice showed that the BiTE antibody eliminated even large numbers of implanted cancer stem cells, resulting in a complete inhibition of tumor growth and survival, while untreated animals with implanted cancer stem cells experienced tumor formation and death.
"We are excited to see how potently MT110 can act against highly aggressive colorectal cancer stem cells," commented Patrick Baeuerle, Ph.D., Chief Scientific Officer of Micromet. "Our new findings are encouraging for the ongoing clinical development of MT110."
(1)Muenz, M. et al. Eradic
|SOURCE Micromet, Inc.|
Copyright©2009 PR Newswire.
All rights reserved